Lantern Pharma Inc.
LTRN
$4.44
-$0.13-2.85%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.25M | -19.88M | -20.78M | -19.09M | -17.75M |
| Total Depreciation and Amortization | 205.00K | 155.80K | 107.50K | 220.50K | 176.30K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 326.90K | 434.80K | 632.50K | -149.30K | 386.70K |
| Change in Net Operating Assets | 850.00K | 166.50K | 2.23M | 1.79M | 1.93M |
| Cash from Operations | -17.87M | -19.12M | -17.81M | -17.23M | -15.26M |
| Capital Expenditure | -7.30K | -11.60K | -12.60K | -14.60K | -16.40K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 10.97M | 7.18M | 3.38M | 192.90K | -254.00K |
| Cash from Investing | 10.96M | 7.16M | 3.37M | 178.20K | -270.40K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 12.00K | 12.00K | 66.70K | 66.70K | 54.70K |
| Repurchase of Common Stock | -- | -- | -- | -500.00K | -500.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 12.00K | 12.00K | 66.70K | -433.30K | -445.30K |
| Foreign Exchange rate Adjustments | -20.30K | -36.90K | -49.50K | 12.90K | -15.50K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.92M | -11.98M | -14.43M | -17.47M | -15.99M |